Abstract: Objective: To approach the present situation for clinical visit, diagnosis and treatment of 263 cases with prostate cancer. Methods: The clinical data for 263 cases with prostatic carcinoma during recent 22 years were divided into 3 groups and were retrospectively analyzed. Results: In recent6 years, 180 new cases have been diagnosed in our hospital. This was 3.67 times the general number ofthe cases in 1983-1992, and 5.29 folds that in 1993-1999. The aging trends in the patients with prostate cancer was obvious (χ2 =5.957, P=0.015). There was no statistical difference between the pro-portion of clinical stage (χ2 =1.146, P=0.564) and the grade of tumor (χ2 =6.696, P=0.153) before and af-ter clinical use of PSA. The chief role of DRE, PSA and TRUS in diagnosis of prostate cancer have been established. Although the number of radical prostatectomy increased, patients receiving endocrine therapy were still in majority. Conclusions: The clinical incidence of prostatic cancer is markedly in-creasing in recent years. The age, clinical stage and tumor grade of prostate cancer do not decrease af-ter clinical use of PSA. Androgen deprived treatment still have important role in clinical control of prostate cancer.